What are the real levers for reducing biologics costs—without compromising innovation or quality?At
#BIO2025 in Boston, our CEO, Himanshu Gadgil, sat down with Joshua(Josh) Abbott of BioProcess Insider to unpack how Enzene is helping biopharma innovators scale smarter through:
● Integrated CDMO services that connect R&D, scale-up, and GMP manufacturing
● The true impact of fully-connected continuous manufacturing (FCCM) vs. semi-continuous setups
● Why our new New Jersey facility is built for biotech companies looking for reliability, flexibility, and speed
● The people and purpose behind “We Are Enzene” — and why it matters for every program
● What’s next for Enzene: innovation, AI-driven efficiency, and global expansion
● Whether you’re a startup building your first biologic or an established player seeking faster, leaner manufacturing—this interview delivers timely insight.
